Company intelligence / Profile preview
Agios Pharmaceuticals
Cambridge, Massachusetts, United Statesagios.com ↗
- Ownership
- Public · AGIO
- Employees
- ~536
- Development stage
- Commercial
01
Overview
Agios has FDA-approved PYRUKYND (mitapivat) for hemolytic anemia in adults with pyruvate kinase deficiency. Previously developed and received FDA approval for IDHIFA (enasidenib) and TIBSOVO (ivosidenib) for acute myeloid leukemia, but sold its oncology portfolio to Servier in 2021. Currently advancing AG-946 in Phase 2 trials for anemia in patients with lower-risk myelodysplastic syndromes, with proof-of-concept achieved in 2023.
- Therapeutic areas
- HematologyOncologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Previously partnered with Celgene (now part of Bristol Myers Squibb)Alnylam (acquired preclinical siRNA program)
04
Financials
- Market cap
- $1.7B
- Total revenue
- $54M
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Agios Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Agios Pharmaceuticals.